Abstract: A compound, pharmaceutical composition, kit for capped RNA transcript, and method for in vitro transcription are provided. The compound has a structure represented by Formula (I), Formula (II), or Formula (III) wherein A1, A2, R1, R2, R9, R10, Q1, Q2, Q3, Q4, Q5, Q6, Y1, Y2, Y3, and Z are as disclosed in the specification.

Abstract: An installation base includes a main body and a release member. The main body includes a first surface and a second surface on two opposite sides. The first surface is provided with a magnet piece. The release member is arranged on a second surface of the main body, and includes a pressing part, a pivoting part and an operating part. The pivoting part is pivotally connected to the main body in a first direction. The pressing part extends from the pivoting part in a second direction perpendicular to the first direction and protrudes from the main body, and a length of the pressing part in the second direction is greater than a thickness from the first surface to the second surface of the main body. The operating part extends from the pivoting part in the second direction toward a direction opposite to the pressing part.

Abstract: A connector includes a base, a connecting part and a coupling piece. One end of the connecting part is connected to the base. The coupling piece is arranged on the other end of the connecting part, and includes a sliding channel having an open end located on a side edge of the coupling piece and an opposite closed end. A maximum linear distance of an outer periphery of the connecting part is less than that of the coupling piece. Another connector includes a base plate, two parallel side plates arranged on the base plate, a front plate connected to the two side plates and having a tapered positioning slot, and a positioning portion arranged on the base plate and adapted for reciprocal movement in a direction perpendicular to the base plate. The base plate, the two side plates and the front plate form an accommodating groove.

Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: An installation base includes a main body and a release member. The main body includes a first surface and a second surface on two opposite sides. The first surface is provided with a magnet piece. The release member is arranged on a second surface of the main body, and includes a pressing part, a pivoting part and an operating part. The pivoting part is pivotally connected to the main body in a first direction. The pressing part extends from the pivoting part in a second direction perpendicular to the first direction and protrudes from the main body, and a length of the pressing part in the second direction is greater than a thickness from the first surface to the second surface of the main body. The operating part extends from the pivoting part in the second direction toward a direction opposite to the pressing part.

Abstract: A connector includes a base, a connecting part and a coupling piece. One end of the connecting part is connected to the base. The coupling piece is arranged on the other end of the connecting part, and includes a sliding channel having an open end located on a side edge of the coupling piece and an opposite closed end. A maximum linear distance of an outer periphery of the connecting part is less than that of the coupling piece. Another connector includes a base plate, two parallel side plates arranged on the base plate, a front plate connected to the two side plates and having a tapered positioning slot, and a positioning portion arranged on the base plate and adapted for reciprocal movement in a direction perpendicular to the base plate. The base plate, the two side plates and the front plate form an accommodating groove.

Abstract: Antibodies and antigen-binding fragments that bind to TIGIT are disclosed. The disclosure further relates to methods and compositions for use in treating an immune-related disease (e.g., a cancer or an infection or infectious disease) by administering a composition disclosed herein.

Abstract: A magnetic mount includes a base and a fixing member. The base includes a lower plate body, an upper stop plate, a lower stop plate and two side stop plates. The upper stop plate and the lower stop plate are respectively provided at a top edge and a bottom edge of the lower plate body, and the two side stop plates are respectively provided at two opposite side edges of the lower plate body. The fixing member includes a base plate and a fixing structure. The base plate has a front surface and a back surface facing each other, wherein the back surface is adapted to be magnetically attached on the lower plate body, and the fixing structure is provided at the front surface and for fixing a media recording device.

Abstract: A magnetic mount includes a base and a fixing member. The base includes a lower plate body, an upper stop plate, a lower stop plate and two side stop plates. The upper stop plate and the lower stop plate are respectively provided at a top edge and a bottom edge of the lower plate body, and the two side stop plates are respectively provided at two opposite side edges of the lower plate body. The fixing member includes a base plate and a fixing structure. The base plate has a front surface and a back surface facing each other, wherein the back surface is adapted to be magnetically attached on the lower plate body, and the fixing structure is provided at the front surface and for fixing a media recording device.

Abstract: The present disclosure provides a peptide for promoting cell migration and/or skin wound healing, including an IL-6-derived peptide, which is designed within the region of the sequence of SEQ ID NO. 1 and of which the sequence includes the sequence of SEQ ID NO. 2, in which the IL-6-derived peptide has about 6-50 amino acids.